We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Warfarin Sensitivity Test Detects Three Genetic Markers

By Labmedica staff writers
Posted on 29 Jul 2008
A warfarin sensitivity test will be used as an aid in the identification of patients at risk for increased sensitivity to the widely used blood-thinning drug, warfarin.

The eSensor Warfarin sensitivity test detects the three genetic markers that are known to play a critical role in metabolism of, and sensitivity to, warfarin. More...
Through detection of these genetic markers, doctors are better able to accurately and efficiently determine the appropriate warfarin dosage level. Individuals respond to warfarin differently, and if its administration is not managed carefully, life-threatening side effects may occur.

Warfarin is the most widely prescribed oral anticoagulant in North America and Europe with an estimated two million new patients in the United States each year. Warfarin is the second-most-likely drug, after Digoxin, to cause adverse events requiring hospitalization. A recent economic study concluded that widespread use of warfarin sensitivity testing in the United States could avoid 85,000 serious-bleeding events and 17,000 strokes a year, saving healthcare costs of approximately US$1 billion annually and improving patient care.

Osmetech plc (Boston, MA, USA) announced that it received 510(k) clearance from the U.S. Food & Drug Administration (FDA; Rockville, MD, USA) for its eSensor A warfarin sensitivity test. The company also received FDA clearance for its second-generation eSensor XT-8 molecular diagnostics platform.

The eSensor XT-8 supports a broad menu of tests and provides accurate results while minimizing technician involvement. The features of the eSensor XT-8 system compare favorably to those of other molecular detection systems. Its ease of use, readily interpretable results, speed, and low maintenance are particularly suited to the needs of the decentralizing market.

James White, CE, Osmetech said, "With key technological and regulatory challenges having now been met, we are confident of further commercial success with the launch of our new eSensor XT-8 platform supported by a growing menu of tests planned to include pharmacogenetics, genetic diseases and infectious diseases.”

Osmetech is an international diagnostics company serving the high growth molecular diagnostic market. It serves hospitals and reference laboratories. Osmetech has a strong portfolio of over 200 issued and pending patents and has launched its first-generation eSensor 4800 platform, an electrochemistry-based array system, together with an FDA- cleared in vitro diagnostic test for cystic fibrosis carrier detection.


Related Links:
Osmetech
U.S. Food & Drug Administration

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Modular Hemostasis Automation Solution
CN Track
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.